-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhelion unit Filament Health expands PEX010 supply deal for Italy psilocybin depression trial

PUBT·09/25/2026 12:49:04
Listen to the news
Rhelion unit Filament Health expands PEX010 supply deal for Italy psilocybin depression trial
  • Filament Health, a wholly owned unit of Rhelion Life Sciences, expanded its supply and license agreement with the University of Chieti-Pescara.
  • The deal increases supply of PEX010 25 mg psilocybin capsules for the TEMPO trial in treatment-resistant depression in Italy.
  • The expansion follows a higher participant target during EU Clinical Trials Regulation review for TEMPO (EU CT 2025-523346-27-00).
  • Filament will provide regulatory support for the trial, including EU release of PEX010.
  • The University sponsors TEMPO; Filament is not responsible for trial conduct.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609250848NEWSFILECNPR____20260925_316036_1) on September 25, 2026, and is solely responsible for the information contained therein.